Legend Operating Income from 2010 to 2026
| LEGN Stock | USD 17.50 0.22 1.24% |
Operating Income | First Reported 2019-03-31 | Previous Quarter -21.9 M | Current Value -43.5 M | Quarterly Volatility 55.9 M |
Check Legend Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Legend Biotech's main balance sheet or income statement drivers, such as Tax Provision of 22.8 M, Depreciation And Amortization of 28.2 M or Interest Expense of 26.1 M, as well as many indicators such as Price To Sales Ratio of 5.18, Dividend Yield of 0.0 or PTB Ratio of 3.12. Legend financial statements analysis is a perfect complement when working with Legend Biotech Valuation or Volatility modules.
Legend | Operating Income | Build AI portfolio with Legend Stock |
Evaluating Legend Biotech's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Legend Biotech Corp's fundamental strength.
Latest Legend Biotech's Operating Income Growth Pattern
Below is the plot of the Operating Income of Legend Biotech Corp over the last few years. Operating Income is the amount of profit realized from Legend Biotech Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Legend Biotech Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Legend Biotech's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Legend Biotech's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Legend Operating Income Regression Statistics
| Arithmetic Mean | (146,309,667) | |
| Coefficient Of Variation | (127.47) | |
| Mean Deviation | 169,329,020 | |
| Median | (1,534,000) | |
| Standard Deviation | 186,504,441 | |
| Sample Variance | 34783.9T | |
| Range | 469.4M | |
| R-Value | (0.83) | |
| Mean Square Error | 11675.9T | |
| R-Squared | 0.69 | |
| Significance | 0.000041 | |
| Slope | (30,574,740) | |
| Total Sum of Squares | 556542.5T |
Legend Operating Income History
About Legend Biotech Financial Statements
Legend Biotech investors utilize fundamental indicators, such as Operating Income, to predict how Legend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -272.9 M | -286.6 M |
Pair Trading with Legend Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Legend Stock
| 0.8 | EVGN | Evogene | PairCorr |
| 0.65 | IMNN | Imunon Inc | PairCorr |
| 0.62 | IPHA | Innate Pharma | PairCorr |
| 0.77 | LYRA | Lyra Therapeutics | PairCorr |
| 0.82 | MBIO | Mustang Bio | PairCorr |
Moving against Legend Stock
| 0.89 | ARWR | Arrowhead Pharmaceuticals | PairCorr |
| 0.81 | MRKR | Marker Therapeutics | PairCorr |
| 0.73 | CING | Cingulate | PairCorr |
| 0.6 | AEON | AEON Biopharma | PairCorr |
| 0.58 | BOLT | Bolt Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Legend Biotech Correlation against competitors. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.7 | Return On Assets | Return On Equity |
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.